190 related articles for article (PubMed ID: 23209030)
21. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.
Mark T; Martin P; Leonard JP; Niesvizky R
Expert Opin Investig Drugs; 2009 Jan; 18(1):99-104. PubMed ID: 19053886
[TBL] [Abstract][Full Text] [Related]
22. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
Griffiths GL; Mattes MJ; Stein R; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Dec; 9(17):6567-71. PubMed ID: 14695162
[TBL] [Abstract][Full Text] [Related]
23. CXCR4 and CD74 together enhance cell survival in response to macrophage migration-inhibitory factor in chronic lymphocytic leukemia.
Thavayogarajah T; Sinitski D; El Bounkari O; Torres-Garcia L; Lewinsky H; Harjung A; Chen HR; Panse J; Vankann L; Shachar I; Bernhagen J; Koschmieder S
Exp Hematol; 2022 Nov; 115():30-43. PubMed ID: 36096455
[TBL] [Abstract][Full Text] [Related]
24. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells.
Lundberg BB; Griffiths G; Hansen HJ
J Control Release; 2004 Jan; 94(1):155-61. PubMed ID: 14684279
[TBL] [Abstract][Full Text] [Related]
25. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin.
Chang CH; Sapra P; Vanama SS; Hansen HJ; Horak ID; Goldenberg DM
Blood; 2005 Dec; 106(13):4308-14. PubMed ID: 16109781
[TBL] [Abstract][Full Text] [Related]
26. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
Kaufman JL; Niesvizky R; Stadtmauer EA; Chanan-Khan A; Siegel D; Horne H; Wegener WA; Goldenberg DM
Br J Haematol; 2013 Nov; 163(4):478-86. PubMed ID: 24112026
[TBL] [Abstract][Full Text] [Related]
27. Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
Li ZH; Zhang Q; Wang HB; Zhang YN; Ding D; Pan LQ; Miao D; Xu S; Zhang C; Luo PH; Naranmandura H; Chen SQ
Invest New Drugs; 2014 Feb; 32(1):75-86. PubMed ID: 23903896
[TBL] [Abstract][Full Text] [Related]
28. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies.
Stein R; Qu Z; Cardillo TM; Chen S; Rosario A; Horak ID; Hansen HJ; Goldenberg DM
Blood; 2004 Dec; 104(12):3705-11. PubMed ID: 15297317
[TBL] [Abstract][Full Text] [Related]
29. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
30. A retroviral mutagenesis screen identifies Cd74 as a common insertion site in murine B-lymphomas and reveals the existence of a novel IFNgamma-inducible Cd74 isoform.
Pyrz M; Wang B; Wabl M; Pedersen FS
Mol Cancer; 2010 Apr; 9():86. PubMed ID: 20416035
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
32. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
[TBL] [Abstract][Full Text] [Related]
33. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
34. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
35. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
36. TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner.
Binsky I; Lantner F; Grabovsky V; Harpaz N; Shvidel L; Berrebi A; Goldenberg DM; Leng L; Bucala R; Alon R; Haran M; Shachar I
J Immunol; 2010 May; 184(9):4761-9. PubMed ID: 20357260
[TBL] [Abstract][Full Text] [Related]
37. CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder.
Choi JW; Kim Y; Lee JH; Kim YS
Int J Urol; 2013 Feb; 20(2):251-5. PubMed ID: 22905972
[TBL] [Abstract][Full Text] [Related]
38. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
Deckert J; Park PU; Chicklas S; Yi Y; Li M; Lai KC; Mayo MF; Carrigan CN; Erickson HK; Pinkas J; Lutz RJ; Chittenden T; Lambert JM
Blood; 2013 Nov; 122(20):3500-10. PubMed ID: 24002446
[TBL] [Abstract][Full Text] [Related]
39. Involvement of CD74 in head and neck squamous cell carcinomas.
Kindt N; Lechien JR; Nonclercq D; Laurent G; Saussez S
J Cancer Res Clin Oncol; 2014 Jun; 140(6):937-47. PubMed ID: 24663824
[TBL] [Abstract][Full Text] [Related]
40. High CD74 expression correlates with ZAP70 expression in B cell chronic lymphocytic leukemia patients.
Butrym A; Majewski M; Dzietczenia J; Kuliczkowski K; Mazur G
Med Oncol; 2013; 30(2):560. PubMed ID: 23572149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]